AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by lipids, metabolites and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GD™, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer.
| Website | http://www.aoadx.com |
| Employees | 56 (22 on RocketReach) |
| Founded | 2020 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+8 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Early Cancer Detection, Cancer Diagnostics, Oncology Diagnostics, Molecular Diagnostics, Tumor Markers, Cancer Screening, Medical Diagnostics, Diagnostic Platform, Precision Oncology, Innovative Diagnostics, Preventative Healthcare, Liquid Biopsy, Cancer Research, Healthcare Technology |
| Competitors | Exact Sciences, Guardant Health, GRAIL, Foundation Medicine, Caris Life Sciences, NantHealth, Freenome, PathAI, Biodesix, Inc., Oncocyte Corporation +45 more (view full list) |
Looking for a particular AOA Dx employee's phone or email?
Oriana Papin-Zoghbi is the CEO and Co-Founder of AOA Dx.
22 people are employed at AOA Dx.
AOA Dx is based in Denver, Colorado.